This phase II trial is testing an oral targeted therapy (adavosertib) in patients with high grade serous ovarian cancer.
This trial is treating patients with high grade serous ovarian cancer.
This is a systemic therapy trial.
You may be able to join this trial if:
- You are able to swallow medication by mouth.
- You have had treatment, but your cancer has come back.
You may be excluded from this trial if:
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A Phase II signal-seeking trial of Adavosertib (AZD1775) targeting recurrent high grade serous ovarian cancer (HGSC) with Cyclin E1 (CCNE1) over-expression with and without gene amplification to determine the clinical benefit rate
Australia New Zealand Gynaecological Oncology Group (ANZGOG)
Eligible patients will receive 300mg of oral adavosertib on Days 1-5 and then Days 8-12 of each 21-day cycle, for a maximum duration of 24 months. Patients eligible to join this trial should be aged 18 and above and have platinum resistant high grade serous ovarian cancer with Cyclin E1 over-expression.
Recruiting Hospitals Read More